泰林生物
(300813)
| 流通市值：12.74亿 | | | 总市值：20.30亿 |
| 流通股本：7605.11万 | | | 总股本：1.21亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 242,467,278.88 | 156,282,129.74 | 80,006,616.11 | 269,856,059.81 |
| 营业收入 | 242,467,278.88 | 156,282,129.74 | 80,006,616.11 | 269,856,059.81 |
| 二、营业总成本 | 236,221,850.45 | 151,988,460.49 | 77,318,177.9 | 264,005,837.7 |
| 营业成本 | 126,295,460.96 | 81,066,133.17 | 44,090,325.94 | 135,681,976.39 |
| 税金及附加 | 2,583,868.59 | 1,747,028.21 | 1,106,636.78 | 3,893,888.37 |
| 销售费用 | 31,709,097.72 | 20,224,732.28 | 9,109,089.68 | 45,038,121.04 |
| 管理费用 | 22,817,792.06 | 15,946,459.52 | 7,455,880.76 | 31,777,042.16 |
| 研发费用 | 49,454,422.64 | 31,252,149.65 | 14,896,419.24 | 58,403,826.62 |
| 财务费用 | 3,361,208.48 | 1,751,957.66 | 659,825.5 | -10,789,016.88 |
| 其中:利息费用 | 11,545,365.77 | 7,679,788.91 | - | 586,832.22 |
| 其中:利息收入 | -8,495,802.75 | 5,933,491.68 | -3,140,247.82 | 11,108,631.73 |
| 加:投资收益 | - | -71,906.25 | - | -11,672.82 |
| 资产处置收益 | - | - | - | -2,158.2 |
| 资产减值损失(新) | -204,971.22 | -213,182.2 | - | -122,669.36 |
| 信用减值损失(新) | -421,208.24 | -856,724.83 | -246,109.05 | -1,288,151.4 |
| 其他收益 | 7,231,506.67 | 4,302,674.23 | 3,397,440.67 | 17,352,964.36 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 12,850,755.64 | 7,454,530.2 | 5,839,769.83 | 21,778,534.69 |
| 加:营业外收入 | 402,698.36 | 343,973.11 | 85,118.24 | 769,086.13 |
| 减:营业外支出 | 658,181.85 | 589,610.77 | 9,106 | 571,695.43 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 12,595,272.15 | 7,208,892.54 | 5,915,782.07 | 21,975,925.39 |
| 减:所得税费用 | 1,995,378.01 | 1,342,713.9 | 374,577.16 | 3,530,733.91 |
| 六、净利润 | 10,599,894.14 | 5,866,178.64 | 5,541,204.91 | 18,445,191.48 |
| 持续经营净利润 | 10,599,894.14 | 5,866,178.64 | 5,541,204.91 | 18,445,191.48 |
| 归属于母公司股东的净利润 | 11,314,672.2 | 6,582,050.48 | 5,873,080.66 | 19,668,950.46 |
| 少数股东损益 | -714,778.06 | -715,871.84 | -331,875.75 | -1,223,758.98 |
| (一)基本每股收益 | 0.1 | 0.06 | 0.05 | 0.18 |
| (二)稀释每股收益 | 0.14 | 0.1 | 0.05 | 0.17 |
| 九、综合收益总额 | 10,599,894.14 | 5,866,178.64 | 5,541,204.91 | 18,445,191.48 |
| 归属于母公司股东的综合收益总额 | 11,314,672.2 | 6,582,050.48 | 5,873,080.66 | 19,668,950.46 |
| 归属于少数股东的综合收益总额 | -714,778.06 | -715,871.84 | -331,875.75 | -1,223,758.98 |
| 公告日期 | 2024-10-30 | 2024-08-29 | 2024-04-24 | 2024-04-24 |
| 审计意见(境内) | | | | 标准无保留意见 |